72% of you would treat some high-risk subclinical arthralgias with MTX and Marta Mosca, in the #EULAR2022 highlights, broadly agrees OP0070 Leiden data showed better function and presenteeism. And that’s a win in my book @RheumNow https://t.co/BqTLy4HBWR https://t.co/cwzJkH0f71